Toxicology Billing Experts

Toxicology Medical Billing Services

Toxicology billing involves drug testing codes that have faced intense regulatory scrutiny and reimbursement reductions in recent years.

Get Your Free Assessment Explore the Guide
Toxicology Medical Billing Services
40%

Of toxicology claims subject to post-payment audit

$3B+

Federal recoveries from toxicology billing fraud

58

Definitive drug class CPT codes (80320-80377)

4x

Maximum annual testing frequency for stable patients

Overview

Compliant Toxicology Billing That Withstands Audit Scrutiny

Toxicology billing involves drug testing codes that have faced intense regulatory scrutiny and reimbursement reductions in recent years. Presumptive drug testing (80305-80307) using immunoassay or instrument-based methods is coded by complexity level, while definitive testing (G0480-G0483) using mass spectrometry or chromatography is coded by the number of drug classes analyzed. Medicare significantly reduced definitive testing reimbursement, and ordering patterns that exceed medical necessity criteria trigger targeted audits.

Clinical toxicology consultations for poisoning management and overdose treatment follow standard E/M coding but require documentation of the specific toxic substance, exposure route, and treatment protocol. Poison control center consultations, antidote administration (J-codes for specific antivenoms and antidotes), and monitoring services must each be coded and documented separately.

Compliant Toxicology Billing That Withstands Audit Scrutiny
Challenges

Common Toxicology billing Challenges We Solve

Every Toxicology billing team deals with payer delays, coding nuance, and collection leakage.

Heightened Payer Scrutiny

Toxicology testing has been a top target for payer audits and federal investigations. Every claim must demonstrate individualized medical necessity, appropriate test selection, and clinical rationale to avoid audit findings and repayment demands.

Presumptive vs. Definitive Test Justification

Payers require documentation explaining why definitive testing was necessary beyond presumptive screening. Routine reflexing of all presumptive results to definitive testing without clinical justification is a red flag for auditors.

Frequency and Volume Controls

Most payers limit the frequency of toxicology testing (commonly quarterly for stable patients) and the number of drug classes tested per encounter. Exceeding these limits without documented clinical justification results in denials.

Standing Order Prohibitions

Blanket standing orders for comprehensive toxicology panels are considered non-compliant. Each test order must reflect the individual patient's treatment plan, risk factors, and clinical circumstances.

Services

Complete Toxicology billing Services

Support spans the full revenue cycle.

Presumptive Drug Testing Billing (80305-80307)

Definitive Testing Coding (80320-80377)

Medical Necessity Documentation Support

Audit Defense and Compliance Monitoring

Individualized Test Order Documentation

Frequency Limit Compliance Tracking

Coverage

Serving Toxicology billing Teams Nationwide

We support independent practices and growing provider organizations.

Independent physician groups

Multi-location practices

Private equity backed platforms

Hospital-owned outpatient groups

Guide

The Complete Guide to Toxicology billing

Toxicology billing demands precision because this specialty has historically attracted significant payer scrutiny and federal enforcement attention. The coding structure divides testing into presumptive (screening) and definitive (confirmatory) categories. Presumptive testing codes (80305 for instrument-assisted, 80306 for instrument-read, 80307 for instrument-assisted with multiple classes) cover initial screening via immunoassay or similar methods. Definitive testing codes (80320-80377) cover specific drug identification by method such as mass spectrometry, with each code representing a specific drug class. The medical necessity for each level of testing must be clearly documented.

CMS and commercial payers have implemented strict utilization controls on toxicology testing following widespread billing fraud cases that resulted in billions in overpayment recoveries. Standing orders for comprehensive panels on every patient are no longer acceptable. Each test must be individually ordered based on the patient’s clinical presentation, treatment plan, and risk factors. Definitive testing should only follow presumptive results that require confirmation or when clinical circumstances specifically warrant bypassing presumptive screening. Our billing team ensures that every toxicology claim is supported by individualized documentation, appropriate frequency, and clinical rationale that withstands audit scrutiny.

Common Questions

Frequently Asked Questions About Toxicology billing

Answers to the questions practice owners ask most often.

Presumptive testing (80305-80307) provides initial screening using immunoassay or similar methods to detect drug classes. Definitive testing (80320-80377) uses techniques like mass spectrometry to identify specific drugs and their metabolites with quantitative results. Each level serves a distinct clinical purpose and must be independently justified.

Frequency depends on clinical circumstances. For stable patients in maintenance treatment, most payers allow quarterly testing. Higher-risk patients (new to treatment, history of non-compliance, medication changes) may justify monthly testing. Each frequency decision must be documented with patient-specific clinical rationale.

Historical billing fraud in toxicology (including unnecessary comprehensive panels, routine definitive testing, and unbundling) led to billions in government recoveries. As a result, CMS and commercial payers now apply heightened scrutiny to all toxicology claims, requiring robust documentation of individualized medical necessity.

Yes, when clinically justified. The presumptive screen may identify unexpected results that require definitive confirmation, or clinical circumstances may warrant both levels simultaneously. Documentation must explain why both levels were necessary for that specific encounter.

There is no universal limit, but testing must be clinically justified for each drug class. Testing for substances the patient is not prescribed, has no history of using, and has no clinical indication for testing is difficult to justify. We help practices develop testing protocols that match clinical risk assessment.

Strong documentation includes an individualized test order (not a standing panel), clinical rationale for each drug class tested, the patient's current medication list, risk factors for substance misuse, treatment plan changes based on results, and evidence that test frequency matches clinical guidelines.

READY TO GET STARTED?

Start Billing Smarter for Toxicology billing

Get a revenue review and a clear action plan tailored to your practice.

Get Your Free Assessment

HIPAA Compliant · No Upfront Fees · No Long-Term Contracts